AutoGenomics | GenomeWeb

AutoGenomics

Premium
AutoGenomics announced Nov. 2 the release of a series of pharmacogenetic ASRs, including CYP 450 2C9 / VKORC1, which can be used to assess warfarin sensitivity.
 
Other applications for the new ASRs include CYP 450 2D6, 2C19, NAT2, UGT1A1, MDR1 and 3A4/3A5 tests.
 
AutoGenomics CEO Fareed Kureshy touted the achievement as “the most comprehensive panel of ASRs made available by any company” and said the achievement positioned the company as a leader in personalized medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.